Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible.

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Chemotherapy-induced cognitive dysfunction in women with breast cancer has become an increasingly important clinical issue. To date, little is known about its incidence, exact characteristics, and exact pathophysiology. Likewise, no treatments have been shown to prevent or decrease cognitive changes thought to result from chemotherapy. However, ongoing scientific research might help us understand the mechanisms that will help patients maintain maximal cognitive function. Changes in cognition due to chemotherapy might result from indirect chemical toxicity and oxidative damage, direct injury to neurons, inflammation, or a type of autoimmune response. Based on these potential causes, and based on interventions that have been tested in dementia and Alzheimer's disease, there are a number of potential, novel interventions that could be tested in clinical trials as treatments for chemotherapy-induced cognitive dysfunction. Possible anecdotal strategies to consider include hormonal interventions, antioxidants, monoamine oxidase inhibitors, growth factors, dopamine agonists, cholinesterase inhibitors, antiinflammatory agents, and behavioral interventions

Original languageEnglish (US)
JournalClinical Breast Cancer
Volume3 Suppl 3
StatePublished - Dec 2002

Fingerprint

Art
Breast Neoplasms
Drug Therapy
Cognition
Monoamine Oxidase Inhibitors
Cholinesterase Inhibitors
Dopamine Agonists
Autoimmunity
Dementia
Intercellular Signaling Peptides and Proteins
Alzheimer Disease
Anti-Inflammatory Agents
Antioxidants
Clinical Trials
Inflammation
Neurons
Cognitive Dysfunction
Incidence
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{6b575a9c2d86462db275ee0c674438bd,
title = "Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible.",
abstract = "Chemotherapy-induced cognitive dysfunction in women with breast cancer has become an increasingly important clinical issue. To date, little is known about its incidence, exact characteristics, and exact pathophysiology. Likewise, no treatments have been shown to prevent or decrease cognitive changes thought to result from chemotherapy. However, ongoing scientific research might help us understand the mechanisms that will help patients maintain maximal cognitive function. Changes in cognition due to chemotherapy might result from indirect chemical toxicity and oxidative damage, direct injury to neurons, inflammation, or a type of autoimmune response. Based on these potential causes, and based on interventions that have been tested in dementia and Alzheimer's disease, there are a number of potential, novel interventions that could be tested in clinical trials as treatments for chemotherapy-induced cognitive dysfunction. Possible anecdotal strategies to consider include hormonal interventions, antioxidants, monoamine oxidase inhibitors, growth factors, dopamine agonists, cholinesterase inhibitors, antiinflammatory agents, and behavioral interventions",
author = "Debra Barton and Loprinzi, {Charles Lawrence}",
year = "2002",
month = "12",
language = "English (US)",
volume = "3 Suppl 3",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer

T2 - the art of the possible.

AU - Barton, Debra

AU - Loprinzi, Charles Lawrence

PY - 2002/12

Y1 - 2002/12

N2 - Chemotherapy-induced cognitive dysfunction in women with breast cancer has become an increasingly important clinical issue. To date, little is known about its incidence, exact characteristics, and exact pathophysiology. Likewise, no treatments have been shown to prevent or decrease cognitive changes thought to result from chemotherapy. However, ongoing scientific research might help us understand the mechanisms that will help patients maintain maximal cognitive function. Changes in cognition due to chemotherapy might result from indirect chemical toxicity and oxidative damage, direct injury to neurons, inflammation, or a type of autoimmune response. Based on these potential causes, and based on interventions that have been tested in dementia and Alzheimer's disease, there are a number of potential, novel interventions that could be tested in clinical trials as treatments for chemotherapy-induced cognitive dysfunction. Possible anecdotal strategies to consider include hormonal interventions, antioxidants, monoamine oxidase inhibitors, growth factors, dopamine agonists, cholinesterase inhibitors, antiinflammatory agents, and behavioral interventions

AB - Chemotherapy-induced cognitive dysfunction in women with breast cancer has become an increasingly important clinical issue. To date, little is known about its incidence, exact characteristics, and exact pathophysiology. Likewise, no treatments have been shown to prevent or decrease cognitive changes thought to result from chemotherapy. However, ongoing scientific research might help us understand the mechanisms that will help patients maintain maximal cognitive function. Changes in cognition due to chemotherapy might result from indirect chemical toxicity and oxidative damage, direct injury to neurons, inflammation, or a type of autoimmune response. Based on these potential causes, and based on interventions that have been tested in dementia and Alzheimer's disease, there are a number of potential, novel interventions that could be tested in clinical trials as treatments for chemotherapy-induced cognitive dysfunction. Possible anecdotal strategies to consider include hormonal interventions, antioxidants, monoamine oxidase inhibitors, growth factors, dopamine agonists, cholinesterase inhibitors, antiinflammatory agents, and behavioral interventions

UR - http://www.scopus.com/inward/record.url?scp=0036982786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036982786&partnerID=8YFLogxK

M3 - Article

C2 - 12533273

AN - SCOPUS:0036982786

VL - 3 Suppl 3

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -